Understand · Treat · Recover
Recurrent Ovarian Cancer
Recurrence needs a new assessment of symptoms, previous treatment, biomarkers and goals—not an automatic repeat of the first regimen.
This guide is educational and does not replace individual medical assessment. Do not start, stop or change treatment without the treating team. Cancer Aware supports patients and families worldwide. Drug approvals, availability, affordability and care pathways vary by country.
Chapter 14 of 20
Confirm what has changed
The team reviews scans, symptoms and marker trends. A rising CA-125 alone does not automatically mean chemotherapy should begin immediately. If the diagnosis or pattern is uncertain, another biopsy may help. Bring a treatment timeline showing drugs, dates, responses and lasting toxicities.
How previous platinum response helps
A longer interval since platinum often predicts greater likelihood of benefit from another platinum combination. Progression during treatment or within roughly six months suggests platinum-resistant disease. This is a clinical spectrum, not a perfect biological switch. Prior response, allergies, cumulative toxicity, previous PARP or bevacizumab use and current symptoms all matter.
Potential treatment routes
When platinum remains appropriate, a platinum combination may be offered, with selected use of bevacizumab and a later maintenance discussion. When platinum is unsuitable, options include weekly paclitaxel, pegylated liposomal doxorubicin, gemcitabine or topotecan, sometimes with bevacizumab when safe. Secondary surgery is reserved for selected patients in whom complete resection is likely; it is not routine for every recurrence.
Biomarker-directed and newer options
- FRα-positive platinum-resistant disease: mirvetuximab soravtansine has a US indication after one to three prior systemic regimens, using an approved test. Eye monitoring and preventive eye care are essential.
- PD-L1 CPS ≥1 platinum-resistant disease: the US FDA approved pembrolizumab with paclitaxel, with or without bevacizumab, in February 2026 after one or two prior systemic regimens. This is a defined combination indication, not a recommendation for immunotherapy alone in everyone.
- Relacorilant with nab-paclitaxel received US approval in March 2026 after one to three prior regimens, including prior bevacizumab. Drug interactions and safety need specialist review.
- MSI-high/dMMR or other qualifying molecular findings may support tissue-agnostic options under the relevant local indication. Low-grade serous disease has a separate treatment pathway.
Choosing together
Ask which option is most likely to improve symptoms or control disease, how much toxicity is expected, and whether a clinical trial is suitable. Availability and approvals vary internationally. When burdens outweigh benefit, symptom-focused care remains active treatment. Stopping an ineffective drug does not mean stopping medical care.
Key takeaway
A new treatment decision should account for what the cancer—and the patient—experienced before.
Common questions
Does recurrence mean no treatment can help?
No. Further treatment may control disease and relieve symptoms, although recurrent epithelial cancer is usually approached as a long-term control problem rather than a promised cure.
Should treatment start for CA-125 alone?
Not automatically; symptoms, scans, preferences and the clinical setting should guide timing.
Can platinum be used again?
Sometimes, depending on the treatment-free interval, response and tolerance.
Is immunotherapy useful for everyone?
No. Biomarker and regimen-specific eligibility is important.
Can recurrence be operated on?
Selected patients may benefit when complete resection is realistically achievable.
Can I choose a treatment break?
A planned break can be discussed with clear monitoring and symptom support.